Background. Intramuscular benzathine penicillin G (BPG) is widely used for the treatment of syphilis. However, BPG is not available in some countries. This study examined the effectiveness and safety of high-dose oral amoxicillin plus probenecid for the treatment of syphilis in patients with human immunodeficiency virus type 1 (HIV-1).
Syphilis is a common sexually transmitted infection caused by Treponema pallidum, and in recent years, an increase in the number of cases with syphilis has been reported among men who have sex with men (MSM), particularly among those with human immunodeficiency virus type 1 (HIV-1) infection in resource-rich settings [1, 2] . A recent study of syphilis [3] in HIV-1-infected men, comprised mostly of MSM, showed that syphilis is associated with an increase in HIV-1 RNA load and with a small decrement in CD4 cell count, suggesting that syphilis may increase a risk of HIV-1 transmission. Furthermore, progression to neurosyphilis may be faster in HIV-1-infected patients than patients without HIV-1 infection [4] [5] [6] , and HIV-1 infection may exacerbate the clinical symptoms of neurosyphilis [7] . For the above-mentioned reasons, early diagnosis and treatment of syphilis are important in HIV-infected patients.
One-shot intramuscular benzathine penicillin G (BPG) injection is widely used for the treatment of primary, secondary, and early latent syphilis based on its high efficacy and convenience [8] [9] [10] ; however, intramuscular injection is painful and, for the treatment of late latent syphilis and syphilis of unknown duration, 3 injections at 1-week intervals (3 hospital visits in total) is required. BPG is not available in some countries, including Japan [11, 12] , and oral amoxicillin plus probenecid has been used as an alternative for BPG in the treatment of syphilis.
However, there is no evidence available on the efficacy and safety of oral amoxicillin plus probenecid for the treatment of syphilis; the only available evidence is from pharmacokinetic studies published in the 1970s-1980s [13, 14] .
We investigated the efficacy and safety of high-dose oral amoxicillin (3 g ) plus probenecid for the treatment of syphilis (excluding neurosyphilis) in patients with HIV-1 infection in an observational setting.
METHODS

Patients and Study Design
We conducted a retrospective cohort study of HIV-1-infected patients with syphilis to investigate the efficacy and safety of oral amoxicillin plus probenecid for the treatment of syphilis at the AIDS Clinical Center, National Center for Global Health and Medicine (NCGM), Tokyo, Japan. The enrollment criteria were HIV-1-infected patients who were diagnosed with syphilis and started treatment with 3 g oral amoxicillin plus probenecid at our center between January 2000 and June 2014. We included all patients treated with the combination of 3 g amoxicillin and probenecid, irrespective of the dose of the latter. The diagnosis of syphilis was based on both serum rapid plasma regain (RPR) titers ≥8 and positive T. pallidum hemagglutination (TPHA) result [15] . The following exclusion criteria were applied: (1) lack of follow-up tests, (2) patients with neurosyphilis diagnosed based on the findings of cerebrospinal fluid (CSF) [16] , or ocular or auditory syphilis, (3) patients who started treatment with antibiotics other than 3 g amoxicillin plus probenecid, (4) patients with clinical symptoms compatible with primary or secondary syphilis but RPR titers <8, (5) patients suspected of reinfection after initiation of syphilis treatment (≥4-fold rise in RPR titer after 4-fold decrement with or without symptoms) [15, 17] .
Data Collection
Data on the following parameters were collected at the time of treatment of syphilis: stage of syphilis infection, age, sex, race, route of HIV-1 infection, antiretroviral therapy (ART) use, history of syphilis treatment, status of hepatitis B and C infection, RPR titer, CD4 count, and HIV-1 RNA load. The stage of syphilis was classified into early syphilis (including primary, secondary, and early latent syphilis) and late syphilis (including late latent syphilis and syphilis of unknown duration) [8, 9] . Early latent syphilis was defined as asymptomatic syphilis that was confirmed to be infected within a year from the day of diagnosis, and late latent syphilis was defined as asymptomatic syphilis confirmed to be infected more than a year before diagnosis [8, 9] . Syphilis with unknown duration was defined as asymptomatic syphilis that could not be classified into either early latent or late latent syphilis [8, 9] . The methods of amoxicillin and probenecid administration, treatment duration, treatment efficacy, adverse events during treatment, and changes to doxycycline from amoxicillin were also collected from the medical records. Among the adverse events, the presence of fever and/or acute exacerbation of maculopapular skin rash within 24 hours of administration of amoxicillin was defined as Jarisch-Herxheimer reaction for syphilis and was not regarded as drug-related adverse events [18] .
Successful treatment of syphilis was defined as at least 4-fold decrement in RPR titer within 24 months after initiation of treatment. Follow-up serum RPR titer was examined at the discretion of the attending physician. Because at our clinic, written informed consent was obtained from each patient to store serum samples at the first and subsequent visits [19] , the RPR data based on stored samples were also used to supplement the RPR data from daily clinical practice order to determine treatment response and the syphilis staging. RPR Test "Sankoh" (EIDIA Co, Ltd, Tokyo, Japan) was used for the measurement of RPR titer both in clinical practice and with stored samples.
Patients visited our clinic at least once every 3 months for monitoring and prescription, as the prescription period under the Japanese healthcare system is limited to 3 months [20] . The study was approved by the Human Research Ethics Committee of NCGM, and was conducted according to the principles expressed in the Declaration of Helsinki.
Statistical Analysis
The study patients were classified according to the results of the combination treatment into the success group ( patients with successful treatment of syphilis) and failure group (failure of treatment). The baseline characteristics were compared between the 2 groups using the Student t test or χ 2 test (Fisher exact test when appropriate) for continuous or categorical variables, respectively. To estimate risk factors for treatment failure, univariate logistic regression model was constructed. Because the number of patients in the failure group was small (n = 13) in this study, the multivariate analysis was not performed. Statistical significance was defined as 2-sided P values <.05. We used odds ratios (ORs) with 95% confidence intervals (CIs) for logistic regression analysis. All statistical analyses were performed with Stata 11 (Stata Corp, College Station, Texas).
RESULTS
During the study period, 403 HIV-1-infected patients were diagnosed with syphilis. One hundred seventeen patients were excluded from the study based on the inclusion and exclusion criteria set for this study (Figure 1 ), and data of the remaining 286 patients were analyzed. All study patients were men with a median age of 36 years (interquartile range Table 2 ). For patients with successful treatment, the median time for the documentation of ≥4-fold decrement in RPR titer after treatment was 4 months (IQR, 3-6 months), and 96.3% of the success group achieved the ≥4-fold decrease in RPR titers within 12 months (Figure 2 ). The median number of follow-up RPRs for the success group and the failure group was 1 (IQR, 1-2) and 4 (IQR, 2-6), respectively, and follow-up RPRs were more frequently measured for the failure group than for the success group (P < .001).
Adverse events related to treatment of syphilis were recorded in 28 (9.8%) patients, with skin rash being the most common symptom (n = 21), followed by fever (n = 9), diarrhea (n = 2), and elevated liver enzymes (n = 1). Furthermore, 5 patients presented with both rash and fever. Analysis of the medical records showed that treatment with amoxicillin was changed to doxycycline in 21 (75%) patients due to the side effects. Despite the adverse events, treatment was considered successful in 25 of the 28 (89.3%) patients. Among the 7 patients who showed adverse events but did not change amoxicillin to doxycycline, treatment was successful in 6, although amoxicillin was administered for the median of only 10 days (IQR, 10-18 days). None of the patients discontinued amoxicillin due to Jarisch-Herxheimer reaction. Logistic regression analysis was performed to identify the risk factors associated with treatment failure. Univariate analysis demonstrated that late syphilis (OR, 3.9 [95% CI, 1.25-12.4]; P = .019) and high HIV-1 load ( per 1 log 10 copies/mL: OR, 1.5 [95% CI, 1.03-2.26]; P = .033) before treatment were associated with treatment failure (Table 3) . On the other hand, older age was associated with successful treatment ( per 1 year: OR, 0.9 [95% CI, .84-.99]; P = .025), and higher CD4 count was also marginally associated ( per 1 cell/μL: OR, 1.0 [95% CI, .99-1.00]; P = .053).
DISCUSSION
The present study investigated the treatment efficacy of 3 g oral amoxicillin plus probenecid for early and late syphilis among HIV-1-infected patients in an observational setting. The results showed that 95.5% of the study patients were successfully treated based on 4-fold decrement in RPR titer. Treatment efficacy was 97.5% in patients with early syphilis (including primary, secondary, and early latent syphilis) and 90.8% in patients with late syphilis (including late latent syphilis and syphilis with unknown duration). This high treatment efficacy is surprising considering that our study population could have included asymptomatic neurosyphilis, because neurosyphilis in HIV-infected patients could occur even in early syphilis without clinical symptoms [5, 6] , and most study patients (94.1%) did not undergo lumbar puncture for CSF examination. Furthermore, because increased rate of treatment failure has been reported in HIV-1-infected patients compared with noninfected patients [21, 22] , the treatment efficacy shown in this study can be generalized to or could be even better among patients without HIV-1 infection. The regimen of 3 g oral amoxicillin plus probenecid was highly tolerable as well; only 28 (9.8%) patients experienced adverse events, and amoxicillin was switched to doxycycline in only 21 (7.3%) patients. It is also noteworthy that treatment of syphilis was successful in 89.3% of the patients who developed adverse events. Thus, high-dose oral amoxicillin (3 g) plus probenecid can be considered the treatment of choice for early syphilis, late latent syphilis, and syphilis of unknown duration where intramuscular BPG is not available or 3 injections of intramuscular BPG at 1-week intervals is not feasible or is inconvenient to patients with late syphilis.
In the present study, the treatment duration for most patients was either for 14-16 days (49.7%) or 28-30 days (34.3%). Comparison of treatment efficacy between early and late syphilis according to treatment duration showed that treatment efficacy was similar for both 2-week and 4-week treatment in early syphilis, whereas it tended to be lower for 2-week than 4-week treatment in late syphilis, albeit statistically insignificant (P = .15). Based on these results and considering that the majority of the study patients used 750 mg of probenecid, we recommend 2 weeks of treatment with 3 g oral amoxicillin plus 750 mg Figure 2 . Time until 4-fold decrement in rapid plasma reagin (RPR) titer after initiation of syphilis treatment for successfully treated patients. The median time until ≥4-fold decrement in RPR titer was 4 months (interquartile range, 3-6 months). The ≥4-fold decrement in RPR titer within 12 months was accomplished in 96.3% of the patients. The number and proportion of patients with ≥4-fold decrement in RPR titer at 1-3, 4-6, 7-9, 10-12, and 13-24 months after treatment initiation were 127 (46.5%), 79 (28.9%), 24 (8.8%), 33 (12.1%), and 10 (3.7%), respectively. probenecid for patients with early syphilis and 4 weeks of treatment using the same doses for patients with late latent syphilis and syphilis of unknown duration. To our knowledge, this is the first study to report the treatment efficacy of high-dose oral amoxicillin plus probenecid for syphilis, regardless of HIV-1 infection status. Although the treatment of oral amoxicillin plus probenecid is described as an alternative syphilis treatment in the UK national guidelines on the management of syphilis [10] , previous studies were either only pharmacokinetic studies that examined amoxicillin level in the CSF, or anecdotal, and all of these studies were published in the 1970s and 1980s [13, 14, 23, 24] . It is also noteworthy that amoxicillin, similar to aqueous penicillin, crosses the blood-brain barrier to reach the causative bacteria in the CSF [13, 25] , whereas BPG, the preferred choice for early and late syphilis, does not [26] . This might be particularly important for patients with HIV-1 infection because these patients likely present with asymptomatic neurosyphilis, and progression to neurosyphilis is faster in HIV-1-infected patients than in noninfected patients [4] [5] [6] . Doxycycline and azithromycin are alternative choices for oral treatment of syphilis for patients with penicillin allergy listed in the guidelines [10] ; however, evidence for treatment efficacy of these regimens is limited, particularly among patients with HIV-1 infection [27] , and unfortunately, emerging resistance of azithromycin for T. pallidum has been reported [28, 29] .
Despite several strengths of our study, such as novelty and large number of patients treated with the same regimen of oral amoxicillin plus probenecid, we acknowledge several limitations. First, cases of early latent syphilis might have been included among those with syphilis of unknown duration, because blood samples 1 year before the diagnosis of syphilis were not necessarily available for all patients. Thus, the treatment efficacy for syphilis of unknown duration might be overestimated. However, because only 5.9% of the study patients underwent lumbar puncture, neurosyphilis might be included in this group as well, suggesting that the treatment efficacy might be underestimated. Second, this study defined successful treatment as a ≥4-fold decrement in RPR titer by 24 months after starting treatment. This criterion was chosen because the serologic response after treatment in HIV-infected patients is slower than that in noninfected patients [21, 30] . Although the long observation period might increase the risk of unexpected antibiotic exposure and might contribute to overestimated treatment efficacy, in this study, 96.3% of patients with successful treatment against syphilis achieved a ≥4-fold decrement in RPR titer within 12 months after treatment (Figure 2) . Third, the retrospective nature of the study could have introduced some selection and information biases. In fact, although all study patients were treated with 3 g amoxicillin plus probenecid, the duration of treatment, frequency of drug administration, and probenecid dose were not identical among the study patients. However, as described above, most patients were treated for either 2 weeks or 4 weeks, and the treatment efficacy was equally high (the efficacy of 2 weeks' treatment tended to be lower than that of 4 weeks among patients with late syphilis, though not statistically significant). Similarly, most (80.8%) patients were treated with amoxicillin 3 times a day, and 60.1% were treated with probenecid 750 mg/day. These are the reasons for recommending 2 weeks of 3 g oral amoxicillin plus 750 mg probenecid for patients with early syphilis and 4 weeks of treatment for patients with late syphilis.
In conclusion, the efficacy of 3 g oral amoxicillin plus 750 mg probenecid daily was very high in HIV-1-infected patients with early and late syphilis. This regimen was also highly tolerable and required only a single hospital visit. Two weeks of this regimen for patients with primary, secondary, and early latent syphilis, and 4 weeks of treatment for late latent syphilis and syphilis of unknown duration are suggested. Three grams of amoxicillin plus probenecid may be an acceptable replacement for intramuscular BPG. Additional prospective studies are warranted.
Notes
